Drug Profile
Research programme: malaria vaccines - Protein Potential
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Protein Potential
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Falciparum malaria; Vivax malaria
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Falciparum-malaria(Prevention) in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Vivax-malaria(Prevention) in USA (Parenteral)
- 19 Jul 2016 Preclinical trials in Falciparum malaria (Prevention) in USA (Parenteral)